Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,339	$ 11,327
Accounts receivable, net		455
Inventories, net		1,029
Assets held-for-sale	400
Prepaid expenses and other current assets	926	299
Total current assets	3,665	13,110
Property and equipment, net	232	1,122
Right-of-use assets		2,342
Deposits and other assets	7	25
Total assets	3,904	16,599
Current liabilities:
Accounts payable	1,588	1,093
Accrued expenses	1,575	1,889
Accrued compensation expense	885	2,698
Accrued clinical trial expenses	733	707
Current operating lease liabilities	106	237
Contract liabilities	335	335
Total current liabilities	5,222	6,959
Long term operating lease liabilities		2,365
Total liabilities	5,222	9,324
Commitments and contingencies
Stockholders’ equity (deficiency):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,657 and 15,643 as of March 31, 2020 and December 31, 2019, respectively	264,003	264,008
Additional paid-in capital	48,892	48,613
Accumulated other comprehensive loss	(543)	(562)
Accumulated deficit	(313,670)	(304,784)
Total stockholders’ equity (deficiency)	(1,318)	7,275
Total liabilities and stockholders’ equity (deficiency)	$ 3,904	$ 16,599